Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

159
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
159
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Ligand Binding Sites02:40

Ligand Binding Sites

11.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
11.9K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

119
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
119

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence empowers the innovation of traditional Chinese medicine.

Journal of integrative medicine·2026
Same author

New patchoulol- and guaiane-type sesquiterpenoids from Sanguisorba officinalis with anti-melanogenic activity.

Natural products and bioprospecting·2026
Same author

Xing-nao-sheng-jiang powder alleviates ischemic stroke in rats by inhibiting pyroptosis-related microglial ETosis: An emerging perspective on microglial ETosis.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

A comprehensive strategy for the rapid identification and analysis of the differences in composition of raw and processed Aconiti Radix.

Journal of pharmaceutical and biomedical analysis·2025
Same author

Cistanoside F Ameliorates Lipid Accumulation and Enhances Myogenic Differentiation via AMPK-Dependent Signaling in C2C12 Myotubes.

Cells·2025
Same author

Luteolin-7-diglucuronide, a novel PTP1B inhibitor, ameliorates hepatic stellate cell activation and liver fibrosis in mice.

Acta pharmacologica Sinica·2024

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.2K

Multi-algorithm and multi-model based drug target prediction and web server.

Ying-tao Liu1, Yi Li1, Zi-fu Huang1

  • 1Drug Discovery and Design Center, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Acta Pharmacologica Sinica
|February 4, 2014
PubMed
Summary
This summary is machine-generated.

A new computational method predicts potential drug targets using only protein sequences. This approach identifies approximately 30% of human proteins as targets and flags many clinical trial candidates as non-targets.

More Related Videos

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

1.3K
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.8K

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.2K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

1.3K
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.8K

Area of Science:

  • Computational biology
  • Drug discovery
  • Bioinformatics

Background:

  • Identifying effective drug targets is crucial for therapeutic development.
  • Current methods often require extensive experimental data.
  • Predicting drug targets solely from protein sequences offers a potentially faster and more cost-effective approach.

Purpose of the Study:

  • To create a dependable computational strategy for identifying potential drug targets using only protein sequence information.
  • To develop predictive models that can distinguish between drug targets and non-targets.

Main Methods:

  • Utilized prepared datasets of known drug targets and non-targets.
  • Employed a multi-algorithm and multi-model strategy.
  • Developed prediction models using Support Vector Machine, Neural Network, and Decision Tree algorithms.

Main Results:

  • Successfully generated 21 prediction models for each of the 3 employed algorithms.
  • Estimated that approximately 30% of human proteins could be potential drug targets.
  • Indicated that around 40% of suspected targets in Phase II clinical trials might actually be non-targets.
  • Launched the D3TPredictor web server for public access.

Conclusions:

  • A reliable and robust method for drug target prediction from protein sequences has been established.
  • The multi-algorithm and multi-model strategy proved effective for accurate prediction.
  • The findings highlight the potential of sequence-based prediction in drug discovery and development.